--- title: "Chugai Pharmaceutical (TSE:4519) Valuation In Focus After First Quarter 2026 Earnings Release" type: "News" locale: "en" url: "https://longbridge.com/en/news/285002179.md" description: "Chugai Pharmaceutical (TSE:4519) reported strong first quarter 2026 earnings with increased sales, revenue, and net income. Despite a 1.59% share price rise on the earnings announcement, the stock has seen a 10.36% decline over the past month. The company is considered undervalued with a fair value estimate of ¥8,571 per share, compared to the last close of ¥8,245. Key investments in manufacturing capacity are expected to enhance profitability, but risks include reliance on specific drugs and potential cost pressures. Investors are encouraged to explore further opportunities in the healthcare sector." datetime: "2026-05-03T18:10:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285002179.md) - [en](https://longbridge.com/en/news/285002179.md) - [zh-HK](https://longbridge.com/zh-HK/news/285002179.md) generator: "portal-rs" --- # Chugai Pharmaceutical (TSE:4519) Valuation In Focus After First Quarter 2026 Earnings Release ## Why the latest earnings and board decisions matter for investors Chugai Pharmaceutical (TSE:4519) has drawn fresh attention after reporting first quarter 2026 results, with higher sales, revenue, and net income versus a year earlier, along with a board review of a trust based stock compensation plan. See our latest analysis for Chugai Pharmaceutical. Despite the first quarter earnings support and the board review of a trust based stock compensation plan, the 1 day share price return of 1.59% contrasts with a 30 day share price return decline of 10.36%. However, the 3 year total shareholder return of 144.63% and 5 year total shareholder return of 123.51% still reflect strong longer term value creation. If this kind of earnings driven story has your attention, it can be worth widening your search to other healthcare names using our screener of 8 healthcare AI stocks With earnings rising, annual revenue and net income increasing, and the share price trading below some valuation estimates, is this an undervalued healthcare leader, or is the market already accounting for future growth? ## Most Popular Narrative: 4% Undervalued Chugai Pharmaceutical's most followed narrative pegs fair value at roughly ¥8,571 per share, a touch above the last close of ¥8,245. This sets up an interesting earnings driven valuation story. > *Significant investment in advanced, environmentally friendly manufacturing capacity (for example, the new UKX research facility) is expected to strengthen Chugai's ability to efficiently scale production of innovative therapeutics, enhancing supply chain resilience and driving better cost control, with a positive impact on future net profit margins.* Read the complete narrative. Want to see what is baked into that near term fair value edge? The narrative leans heavily on steady top line growth, rising margins, and a richer earnings multiple that has to hold up years from now. **Result: Fair Value of ¥8,571 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Chugai offsetting reliance on Hemlibra and Actemra, while also managing pricing pressure and higher costs that could squeeze margins. Find out about the key risks to this Chugai Pharmaceutical narrative. ## Next Steps With mixed views around earnings, valuation, and future growth, it makes sense to review the full picture yourself, including both the concerns and the potential benefits. Take a closer look at the 4 key rewards and 1 important warning sign ## Looking for more investment ideas? Do not stop your research with Chugai Pharmaceutical alone. Broaden your shortlist with focused stock ideas that fit clear goals, risk levels, and income needs. - Target potential mispricing by scanning for quality names trading below some estimates of worth with the 17 high quality undervalued stocks. - Strengthen the defensive side of your portfolio by checking companies in the 46 resilient stocks with low risk scores that score well on resilience. - Get ahead of the crowd by reviewing the screener containing 58 high quality undiscovered gems before these names land on everyone else's radar. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [4519.JP](https://longbridge.com/en/quote/4519.JP.md) - [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) ## Related News & Research - [Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal](https://longbridge.com/en/news/296167792.md) - [Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment](https://longbridge.com/en/news/295890880.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline](https://longbridge.com/en/news/296030806.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**